Individualized management of advanced bladder cancer: Where do we stand?

Urologic Oncology
Earle F Burgess

Abstract

Despite recent progress in the development of novel targeted therapies in various malignancies, the management of advanced urothelial cancer has changed little over the past 2 decades. Comorbidities inherent to patients with bladder cancer often preclude the use of standard cisplatin-based chemotherapy and underscore the need for individualized treatment recommendations and the development of more effective therapies. This review discusses current issues relevant to the management of patients with locally advanced and metastatic urothelial carcinoma of the bladder and highlights recent advances in defining molecular aberrations that may ultimately lead to personalized therapeutic decision making.

References

Nov 10, 1994·The New England Journal of Medicine·D EsrigR J Cote
Jun 13, 2003·Lancet·UNKNOWN Advanced Bladder Cancer Meta-analysis Collaboration
Aug 29, 2003·The New England Journal of Medicine·H Barton GrossmanE David Crawford
Sep 1, 2005·The Lancet Oncology·Núria MalatsFrancisco X Real
Dec 7, 2005·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·C N SternbergUNKNOWN EORTC Genito-Urinary Cancer Group
Apr 21, 2007·The Journal of Clinical Investigation·Chee-Onn LeongLeif W Ellisen
Aug 2, 2007·Proceedings of the National Academy of Sciences of the United States of America·Jae K LeeDan Theodorescu
Sep 14, 2007·Acta Oncologica·Anne Birgitte AlsHans Von Der Maase
Dec 1, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Ben GeorgeRichard J Cote
May 20, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Michael J O'Connell
Aug 12, 2009·International Journal of Radiation Oncology, Biology, Physics·Nicholas P MunroRohit Chahal
Oct 1, 2009·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Fiona M PlattMargaret A Knowles
Aug 10, 2010·Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada·Brendan J W MilesBernhard J Eigl
Aug 26, 2010·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Martin LaussMattias Höglund
Jan 25, 2011·The Lancet Oncology·Steven Christopher SmithDan Theodorescu
May 6, 2011·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M D GalskyG Sonpavde
May 11, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Matthew D GalskyJoaquim Bellmunt
Jul 21, 2011·International Journal of Urology : Official Journal of the Japanese Urological Association·Kazuhito MatsushitaShahrokh F Shariat
Aug 4, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Walter M StadlerRichard J Cote
Jan 19, 2012·PloS One·Woonyoung ChoiArlene Siefker-Radtke
May 4, 2012·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Gottfrid SjödahlMattias Höglund
May 19, 2012·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Rafael Morales-BarreraJoan Carles

❮ Previous
Next ❯

Citations

Jul 28, 2016·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·Robert IlievOndrej Slaby

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Sequencing

Several sequencing approaches are employed to understand and examine tumor development and progression. These include whole genome as well as RNA sequencing. Here is the latest research on cancer sequencing.

Bladder Carcinoma In Situ

Bladder Carcinoma In Situ is a superficial bladder cancer that occurs on the surface layer of the bladder. Discover the latest research on this precancerous condition in this feed.

Cancer Genomics (Keystone)

Cancer genomics approaches employ high-throughput technologies to identify the complete catalog of somatic alterations that characterize the genome, transcriptome and epigenome of cohorts of tumor samples. Discover the latest research using such technologies in this feed.